What Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?

KARAMAN A.

EURASIAN JOURNAL OF MEDICINE, cilt.52, sa.1, ss.98-99, 2020 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Kısa Makale
  • Cilt numarası: 52 Sayı: 1
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5152/eurasianjmed.2020.19238
  • Dergi Adı: EURASIAN JOURNAL OF MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.98-99
  • Anahtar Kelimeler: ARDS, bosentan, pharmacological treatment, LESIONS
  • Atatürk Üniversitesi Adresli: Evet

Özet

Acute respiratory distress syndrome is characterized by dyspnea at presentation, tachypnea on physical examination, findings of bilateral infiltration in chest radiography, refractory hypoxia, and high mortality. Although the main treatment approach is to address the underlying disease, there are also pharmacological and nonpharmacological options for supportive treatment. There is currently no pharmacological agent with proven efficacy in this syndrome, and many drugs are being studied for this purpose. One of these is the endothelin receptor antagonist bosentan.